Construct, face and predictive validities are necessary for any disease model. Although rodent models are used to investigate the neurobiology of autism, however, till date there is no such ideal animal model which can fulfill all the above said validities. Available drug therapy to treat autism is very limited and less effective. In this review, we summarize the work done with rodent models of autism and highlight different validities. We found that, very few studies have studied all the validities in a single study and none of the study fulfilled all the validities. We also reviewed the drugs used in the treatment of autism. Here we propose the limitations of available animal models. We also propose the urgent need of additional models to fulfill all the validities and to understand autism in a better way.
Introduction
According to Diagnostic and Statistical Manual (DSM) IV, autism has been defined as a pervasive developmental disorder (PDD) involving three main domains as a symptomatic phenotype: (1) altered social communication, (2) inflexible language and, (3) repetitive sensorymotor behavior 1 But DSM V has redefined Autism Spectrum Disorder (ASD) symptoms into dyads as (i) Social interaction and social communication deficits; (ii) Restricted, repetitive patterns of behavior, interests, or activities. 2 It has been reported that autism is caused by the environmental factors only, but recent reports are in the favor of involvement of neurodevelopmental and genetic factors too. 3, 4 Although, the children who are born with autism, can be diagnosed by 2-4 years, 5, 6 yet the child suffers with autism throughout the whole life because there is no effective treatment for this disorder till now. In the pathogenesis of autism, genetic, environmental and neurobiological factors are very crucial in which imbalance of the inhibitory-excitatory system plays an important role beside other factors like immune dysregulation and oxidative stress. 7 Therefore, animal models should mimic the parameters and factors, that are considered as developmental precursors of anatomical, functional and behavioral manifestations. Future studies on these manifestations may help elucidate the factors and processes that bring about the unfolding of autistic behavior.
Animal model and diseases
Some neurodevelopmental disorders like autism are strictly limited to humans. The interview is the best method to assess autism and in human where language plays an important role, but in animals we can assess the symptoms of autism by their specific behavioral parameters. Mice, rats, guinea pigs and voles (Microtus) have been already reviewed as animal model of and for autism. 8 Experiments on these models are easy and can be helpful to find out the mechanism of action of particular pathway which is involved in the pathogenesis of ASD. Now a days people are working on zebrafish (Danio rerio) and fly (Drosophila sp.) model system that help to study key molecules and pathways of dysfunctional neurodevelopmental processing in autism. 9, 10 Due to low maintenance cost, small size, embryonic transparency and rapid development life cycle in these two species, it will have the advantage and make these species an attractive genetic and molecular experimental model yet they don't mimic all of the construct validity. In the future research on the cause and cure for autism, animal model will play a very important role.
In most of the studies (Table 1) investigator has used only one causative agent, either chemical or genetic to produce the disease in the animal. As recent reports are in the favor of involvement of neurodevelopmental and genetic factors in autism, 3, 4 besides the environmental factors so that the used causative agent should also use the combination of the above said factors. Interaction of molecular and environmental factors cannot be studied in humans, so we need an animal model to study autism. Currently, no specified accepted animal model of and for autism has been developed, although research on primates and rodents are on peak. The main challenge lies in the fact that an animal model relevant to a psychiatric condition in human like ASD should fit several criteria ( Figure 1 ) usually described as a construct, face and predictive validity.
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Construct validity mainly relies upon the identity of causation between the animal phenotype and the human disease. Face validity implies that the phenomenological aspect observed in the animal is similar to the one observed in patients and predictive validity means that treatments that suppress or reduce some of the symptoms of the disease in humans also reduce the symptoms found in the animal model.
Present animal models and their limitations in autism
Most experimental observations of autism explain the correlation with the different parameters and these correlations often exist without any base. In experimental studies of autism the definite causal relationship between the parameters is required and that must be established in one model organism. Structural, functional and cognitive studies demands bridging all the parameters from genetics to biochemistry. Here we have analyzed few animal models of autism and found that in none of the model both molecular and behavioral parameters were assessed which are the key diagnostic criteria for autism.
A AN NN NA AL LS S COMP REVIEW Although autistic like behavior is expressed by the model organisms, but final diagnosis of autism is still far way away in current scenario. However, the prefrontal cortex is highly implicated in autism and responsible for the alteration in functions related to cognition, language, sociability and emotion, 13 but the author didn't study these parameters. In one of the research author study the effect of sodium valproate (VPA) in children exposed in utero and demonstrated similar behavioral and neuroanatomical abnormalities as reported in autistic animals. 15 The neurodevelopmental effects of this antiepileptic agent were examined in mice following its pre-or postnatal administration, but the connection with molecular parameters was lacking in the study.
Multiple case studies have explained an association of autism and epilepsy. [19] [20] [21] Comorbidity study of autism and epilepsy might pull doors towards treatment of Autism Spectrum Disorder.
A AN NN NA AL LS S COMP REVIEW

Co morbidity of autism and epilepsy
Autism shows some followup disease like epilepsy or seizures. 22 Clinical and pathophysiological studies between autism and epilepsy gives evidence of comorbidity. Approximately 30% autsitic children show epilepsy associated symptoms that is continued upto adolescence, and a substantial, but smaller, the proportion of children with epilepsy is on the autism spectrum. [23] [24] [25] There are various reports showing variable incidence rate, but the rate is sufficiently high to understand the seriousness of this comorbidity. Some studies show the incidence of epilepsy in the autistic individual to be between 5-40%. ASD frequently occurs along with other mental impairments, such as learning disability, seizure disorders, and attention deficit hyperactivity disorder (ADHD). Autism-epilepsy phenotype helps to identify the complex relationship between ASD and epilepsy. This complexity is one of the factors that explain the reason of poorer cognitive behavior in co-expressed ASD-epilepsy patient than those in autism or epilepsy alone. 26, 27 Comorbidity can account via shared neuronal network between autism and epilepsy that leads to imbalance in excitatory/inhibitory pathways, abnormalities in connectivity and disrupted synaptic plasticity. ASD and epilepsy associated fragile X syndrome (FXS), rett syndrome (RTT) and tuberous sclerosis (TSC) can be the result of genetic alteration. The severity of impairment and symptoms associated with autism or with particular epilepsy syndromes reflects focal or global, structurally abnormal or dysfunctional neuronal networks. Pathophysiology of autism can be understood not only by studying epilepsy phenotypes, common molecular and genetic mechanism also help as well. The autism-epilepsy phenotype provides novel model to study new interventions in studying positive modulating effects on social cognitive outcome. 28 Autism is strongly correlated with reduced neuronal cell size and increased cell packing density confined to the limbic system, including the hippocampus, the amygdala, entorhinal cortex, anterior cingulate cortex, mammilary bodies, and the septum. 29, 30 Along with these reports some report shows decreased dendritic complexities in Golgi staining of hippocampal pyramidal cells in autistic condition. 31 Further research have been verified the seizures associated malformations by studying altered GABAergic interneurons packing in CA1 and CA3 hippocampal subfields. 30 Further research defined only behavioral parameter in the support of ASD model induced by epilepsy. 32 Abnormal EEG reports of focal and localized epilepsy also demonstrated developmental regression, intellectual disability and some autistic like features. 33 Now a days research in ASD is on a very advanced stage and enough number of reports suggest that for a perfect model for ASD both the behavioral and molecular parameters should be evaluated in a same model organism and these parameters should show the connection with early suggested studies. Few of the studies have evaluated the molecular parameters, 17 but their behavioral phenotypes remain to be controversial or not evaluated. Therefore, to obtain optimal diagnostic approach, validated data collection and appropriate longitudinal follow-up may help in treatment services in both epilepsy and autism.
Autism and translational research
In case of autism, translational research is very much needed. In translational research, we can replicate some specific brain behavior relationship in children with autism to develop an animal model of the same. A study has shown the differential exploration behavior in the autistic and normal child due to smaller cerebellar vermis. 34 Such type of study can be designed to develop the animal model for autism to investigate the genetic or nongenetic cause of autism. Study on mutant GS guinea pig with malformation of cerebellar vermal lobules, 35 Purkinje cell degeneration mutant mice 36, 37 and rat with cerebellar lesions 38 show differential exploration behavior.
Drug therapy in autism
Currently, there is no specific drug in the market that is approved to treat symptoms of autism. Different pathobiological targets have been reported to be linked to autism in previous clinical and preclinical studies that may help to find a pathway to develop a new drug for the treatment of autistic children. Fig 2 summarizes the percentage of various drugs under different developmental stages. 39 These drugs act on different targets and help to cure the behavioral as well as neurological symptoms.
Disrupt neuroregulation of opioid systems in the body, considered to be involved in impaired social communication in autistic patients. 40 Fluctuated doses of morphine and the endogenous opioid β-endorphin act in opposite ways to each other such as low doses stimulate the frequency of social interaction in animals whether higher doses disrupt it. In maternal-infant attachment studies also reported the opiods influence on feelings of social comfort and blocking separation distress reactions. 41 These studies supports the involvement of opioid systems in formation of social bonding in human that is generally altered in autism. 42, 43 Neuropeptide Org 2766 and Brain imaging, neurochemical and genetic studies have been suggested the association of monoaminergic neurotransmitter systems (dopamine, noradrenaline, serotonin etc) in pathophysilogy of the psychiatric disorders such as hyperactivity disorder, 44 mood disorder, 45 Obsessive Compulsive Disorder (OCD), 46 anxiety disorder, 47 and schizophrenia and these neurotransmitters are affected by the medications. In autism the involvement of these neurotransmitters are not necessary and that is why the drug treatment in autism is not that much effective as in other psychiatric disorders.
Conclusion
Autism can be diagnosed only by the behavioral parameters in the clinical setup. It is very hard to replicate autism in animal models with all the clinical hallmarks. Based on Figure 1 , an animal model of autism would show impairment in social interaction, communication with repetitive behavior. Beside these behavioral parameters all the molecular marker of autism should be also defined in an animal model of autism. Proper evaluation of both behavioral and molecular parameters in the same animal model can give us the better animal model of autism.
Future perspective
However, to produce an animal model of autism by using only one chemical or one mutation in particular gene do not fulfill the construct validity of the model. The face validity of animal model of autism solely based on behavioral assays would be incomplete. The construct, face and predictive validity must be fulfilled by any successful animal model of autism to replicate a combination of the behavioral, neuropathological, immunological, biochemical and genetic basis for autistic disorder. The use of greater number of causative agents in the development of the model can give us more realistic animal model of autism. As the drug therapy is very limited for autism, so that we need a drug urgently for this disease. For the drug development process, a successful animal model of disease is very much required. More than one pathway is involved in the pathogenesis of autism, so we require a drug or any herbal compound that can act on all the affected pathways.
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